Are Peptides Legal? What FDA’s 2026 Lists Say

Some peptides are legal prescription drugs, and most of the ones sold online are not. Semaglutide, the drug in Wegovy and Ozempic, is an FDA-approved peptide drug. BPC-157, TB-500, MOTS-c and most other “research peptides” have no approval for any use and are not on the list of substances a US pharmacy may use to compound. FDA’s April 2026 update lists them as “withdrawn” from its safety-risk category, and that did not make them legal to compound. In an interim policy dated October 28, 2026, HHS said it does not intend to take enforcement action against 503A pharmacies that compound six of them (BPC-157, TB-500, Epitalon, Semax, KPV and MOTS-c) under strict conditions.^[22] That interim policy is not an approval, and it leaves every other research peptide where it was.

Three different questions hide inside “is it legal?”

Sellers and critics both blur these together, so it helps to pull them apart.

1. Is it an FDA-approved drug? If yes, a doctor can prescribe the approved product and a pharmacy can dispense it. Semaglutide (Wegovy, Ozempic, Rybelsus) is in this group.^[15][16] BPC-157 and TB-500 are not.
2. May a pharmacy compound it? A compounding pharmacy mixes a drug for one patient from raw ingredients. Federal law limits which raw ingredients it may use, and most research peptides fall outside those limits.^[1] Under an interim policy dated October 28, 2026, HHS does not plan to pursue 503A compounding of six of them, under set conditions.^[22]
3. Does a “research use only” label change anything? For a seller whose website shows the product is meant for people, FDA says no.^[13]

The lists that decide what a pharmacy may compound

Under section 503A of the Food, Drug, and Cosmetic Act, a state-licensed pharmacy may compound only from ingredients that meet one of three tests: the ingredient has a USP or NF monograph, it is already an ingredient in an approved drug, or it appears on FDA’s 503A bulks list.^[1] A 503A pharmacy also needs a prescription written for one specific patient.^[5]

The 503A bulks list is short. It names six substances, among them Brilliant Blue G and cantharidin for topical use. None is a peptide.^[4] While FDA works through nominations for that list, an interim policy sorts nominated substances into three categories:^[1]

Two details matter for peptide buyers. First, FDA says it does not intend to place substances nominated on or after January 7, 2025 into any of these categories, so a newly nominated peptide gets no interim cover.^[1] Second, a substance that is on none of these lists and meets none of the three tests has no 503A route at all.

Outsourcing facilities, regulated under section 503B, are a separate channel. They follow manufacturing-quality (CGMP) rules and are inspected by FDA on a risk-based schedule.^[5] FDA’s safety-risk list marks each entry as 503A, 503B or both, which is why a peptide can be restricted in one channel and not named in the other.^[3]

What the April 2026 update shows, and why it is not a green light

FDA’s web page listing bulk substances it says may carry significant safety risks, current as of April 22, 2026, now has two tables. The first is the active Category 2 list. The second is headed “Bulk drug substances nominated but withdrawn”, which FDA describes as substances “previously in category 2” that “were withdrawn by the nominators.”^[3]

Most of the peptides sold online now sit in that second table: BPC-157, TB-500 (listed as thymosin beta-4 fragment), MOTs-C, KPV, CJC-1295, epitalon, Semax, selank, emideltide (DSIP), thymosin alpha-1, cathelicidin LL-37, Melanotan II, AOD-9604, PEG-MGF, dihexa acetate and injectable GHK-Cu.^[3] FDA kept its safety notes for each. For CJC-1295, FDA points to serious adverse events, among them a faster heart rate and a vasodilatory reaction. For Melanotan II, it cites published case reports of “melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism.”^[3]

Several of these peptides were then put back in front of FDA’s Pharmacy Compounding Advisory Committee, which advises the agency.^[5] Its July 23 and 24, 2026 meeting took up BPC-157, KPV, TB-500 and MOTs-C on the first day and emideltide, Semax and epitalon on the second, each as a candidate for the 503A bulks list.^[6] FDA’s own briefing documents for BPC-157, TB-500, MOTS-c and KPV each conclude that “a balancing of the criteria weighs against” adding them.^{[7][8][9][10]} Those documents also say FDA “will not issue a final determination” until it has considered the committee’s input.^[7]

FDA itself has not published how the committee voted. As of October 15, 2026, the meeting page offers the briefing documents, the questions, the agenda, the roster and the agency’s slides, but no summary minutes and no tally.^[6] Reporters who covered both days fill that gap. According to Healio, AJMC and Pharmaceutical Executive, the committee sided against FDA’s reviewers on six of the seven peptides and turned down only emideltide.^[17][18][19] Healio reported that the free-base and acetate forms of each peptide were voted on separately and came out the same way.^[17]

A favorable vote is a recommendation, not a change in status. FDA’s meeting page describes the committee’s advice as non-binding, and Pharmaceutical Executive reported that putting any of these peptides on the list would take formal rulemaking.^[6][19] By October 15, 2026, FDA had proposed no such rule, and the regulation that holds the 503A bulks list, last amended in 2019, still contains no peptide.^[4] HHS then acted without a rule, as the next section explains.

The committee’s earlier peptide votes, by contrast, are on FDA’s own record. Minutes of its December 4, 2024 meeting record members turning down AOD-9604 by 12 votes to none, each form of thymosin alpha-1 by 17 to 4, and four of the five CJC-1295 forms by 13 to none, with CJC-1295 acetate rejected 12 to 1.^[20] A further meeting on GHK-Cu, LL-37, dihexa acetate, Melanotan II and PEG-MGF is promised before the end of February 2027, but FDA has not yet announced a date.^[21]

The HHS policy of October 28, 2026

HHS published an interim enforcement policy on October 28, 2026 covering six of the peptides the committee backed: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Emideltide, which the committee turned down, is not included.^[22] For as long as no final rule has settled whether each one joins the 503A bulks list, HHS does not intend to take enforcement action against licensed pharmacies or physicians that compound one of the six under section 503A, provided they meet every condition in the policy.^[22] HHS presents the policy as a way to draw buyers away from research-use-only peptides made by overseas suppliers, which it calls a safety risk.^[22]

The policy does not approve these peptides and does not put them on the 503A bulks list. It covers compounding under section 503A, and HHS reserves the right to narrow or withdraw it if safety or quality problems surface.^[22] The Federal Register notice of October 30, 2026 labels it a draft with no binding force on HHS or on the public, and gives two weeks for written comments.^[23] Each peptide is covered only in a named form and by named routes:^[22]

The other conditions apply to all six.^[22] The product needs a prescription written for one patient and may contain only one active ingredient, so blends and stacks fall outside the policy. The raw powder has to be made at an FDA-registered plant, and its certificate of analysis has to report tests for identity, strength, purity, endotoxin, microbes, heavy metals and other impurities and name the plant that made it. Compounders file serious adverse event and quality reports through MedWatch, FDA’s reporting system, and the patient label explains how to file one. The label must state that the product is compounded and may not be resold. An oral form needs records showing it is adequately absorbed in humans, and the only drug delivery device the policy names is an FDA-cleared syringe. Semax is limited to intranasal use, and the policy does not say which nasal device is acceptable.

None of this says the peptides work. For the human evidence on each, see our reviews of BPC-157, TB-500, MOTS-c, KPV, epitalon and Semax.

Peptide status on FDA's lists, October 2026

This table covers peptides that FDA’s lists name. A peptide missing from it is not cleared by omission: hexarelin, for one, appears on none of FDA’s lists because nobody nominated it. Check any peptide in our peptide status checker.

Sources for the table: FDA’s category lists (updated May 14, 2026), its safety-risk page (April 22, 2026), the 503A bulks list in 21 CFR 216.23, the July 2026 briefing documents and the HHS policy of October 28, 2026.^{[2][3][4][7][22]} GHK-Cu has moved twice this year. FDA removed it from Category 1 on April 22, 2026, when the nominations were withdrawn, then added the non-injectable form back after one nominator clarified on May 5 that it meant to withdraw only the injectable route. FDA says it will consult the advisory committee on GHK-Cu before the end of February 2027.^[2]

Of FDA’s three categories, only Category 1 comes with a stated intent not to act against a compounder, and even that is conditional and interim.^[1] The HHS policy works the same way for its six peptides.^[22] Neither is an approval, and neither says anything about whether a product works.

What “research use only” means legally

Many peptide sites print “research use only” on the vial, or warn that the contents are not meant for people. FDA looks past the label to how the product is sold. In its December 2024 warning letter to Summit Research Peptides, FDA wrote: “Despite statements on your product labeling marketing your products as ‘RESEARCH USE ONLY’ and ‘INTENDED AS A RESEARCH CHEMICAL ONLY,’ evidence obtained from your websites establish that your products are intended to be drugs for human use.”^[13] Because the products were unapproved new drugs, FDA said selling them across state lines violated the Act.^[13]

FDA’s consumer page on GLP-1 drugs says the same about that market: companies have put false research-only labels on semaglutide, tirzepatide, retatrutide, survodutide and similar drugs, then sold them straight to consumers along with dosing instructions, and FDA “urges consumers not to purchase these products which are of unknown quality and may be harmful to their health.”^[14] For how this plays out with tirzepatide specifically, see buying tirzepatide as a research chemical, and for how a research-labeled vial differs from a peptide compounded under the October 2026 HHS policy, see research use only vs compounded peptides.

Peptides that are approved drugs, and where the line sits

“Peptide” is a chemical description, not a legal status. The approved peptide drugs, with each label’s use, are listed in FDA-approved peptides. The GLP-1 drugs are peptides: the Rybelsus label notes that semaglutide’s “peptide backbone is produced by yeast fermentation.”^[16] What each one is built from, and why FDA regulates them as drugs rather than biologics, is in are GLP-1 drugs peptides? Wegovy, as an injection and as a tablet, is FDA-approved to reduce excess body weight in adults who have obesity, and in adults who are overweight and have at least one weight-related condition; the injection is also approved for children 12 and older with obesity.^[15] Those approved products are the legal way to get semaglutide.

Compounded versions are a different matter. FDA says a compounded drug carries no FDA approval and gets no agency check of its safety, effectiveness or quality before sale, and that federal law bars compounders from using retatrutide or cagrilintide at all.^[14] Our guide to what cannot legally be compounded covers the GLP-1 side in detail.

Tesamorelin shows how an approval can still leave no compounding route. It is sold as Egrifta, but FDA lists it among the drug approvals that were deemed biologics licenses on March 23, 2020.^[12] From that date, FDA said, those products “will not be eligible for the exemptions for compounded drugs under sections 503A and 503B.”^[11] Brand Egrifta can be prescribed. A compounded tesamorelin has no route through either channel.

How to check a peptide seller

1. Find the peptide in the table above or in our status checker. If it is withdrawn, in Category 2 or 3, or on no list, a pharmacy has no 503A route to compound it. The exception is the six peptides in the HHS policy of October 28, 2026, and only within that policy’s forms, routes and conditions.^[22]
2. Ask who dispenses it. A lawful compounded product comes from a named, state-licensed pharmacy or a registered outsourcing facility, on a prescription written for you. Our pharmacy verification guide shows how to check a license.
3. Read the label and the marketing together. A vial marked “research use only” next to dosing advice is the pattern FDA has cited in its warning letters to peptide sellers.^[13]
4. Check the evidence separately from the law. Legal status says nothing about whether a peptide works. Our review of which peptides have human trials covers that question, and what FDA said about BPC-157 goes deeper on the most popular one.

Each peptide guide on our peptides hub lists the telehealth sellers we track that offer it, so you can see who prescribes what before you pay. Read more than one page of a seller’s site, because they do not always agree. Viking Alternative Medicine lists BPC-157 among the peptides it carries, while another page on its site says clinics “can no longer legally prescribe” it. Some leave the prescriber out entirely: Prestige Health Rx lists BPC-157, sermorelin and GHK-Cu among its peptides but names neither the medical group that prescribes them nor the pharmacy that fills them.

Many GLP-1 sellers now add peptides to the same account, and the steps above apply to those add-ons too. NAD+, which sits in Category 1 in the table, is on the menu at Joey Med, Bodi Envi and MANÜ Telehealth. Stealth Health lists it as well.

Sermorelin does not appear in the table at all, which is a reason to ask the pharmacy question before you pay, not a sign it is cleared. bmiMD, RNK Health and ReadyRx list it beside their compounded GLP-1 plans, and so do Ark Health and SynergenX Health. Ways2Well works the other way around: it is a lab-based clinic that prescribes peptides after a clinician consult and no longer sells semaglutide or tirzepatide.

Common questions